Perrigo confirms settlement of generic version of Ofirmev injection

Perrigo (PRGO) confirmed that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev injection brought by Cadence (CADX). Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.

View Comments (0)